Jeremy Grantham Biogen Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

$29.2 Billion
Q2 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $10.8 Million - $12.2 Million	-42,707 Reduced 42.94%	56,740 $14.6 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $11.3 Million - $13.1 Million	-41,055 Reduced 29.22%	99,447 $28.3 Million
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $1.39 Million - $1.58 Million	5,400 Added 4.0%	140,502 $39.1 Million
Q4 2022 Feb 13, 2023	SELL	$252.44 - $306.72 $1.44 Million - $1.75 Million	-5,698 Reduced 4.05%	135,102 $37.4 Million
Q3 2022 Nov 10, 2022	SELL	$194.69 - $268.46 $77,876 - $107,383	-400 Reduced 0.28%	140,800 $37.6 Million
Q2 2022 Aug 12, 2022	BUY	$187.54 - $223.02 $2.57 Million - $3.06 Million	13,700 Added 10.75%	141,200 $28.8 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $5.5 Million - $6.93 Million	28,400 Added 28.66%	127,500 $26.9 Million
Q4 2021 Feb 11, 2022	BUY	$223.92 - $287.77 $1.28 Million - $1.64 Million	5,700 Added 6.1%	99,100 $23.8 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $4.08 Million - $5.31 Million	14,400 Added 18.23%	93,400 $26.4 Million
Q2 2021 Aug 12, 2021	BUY	$259.0 - $414.71 $1.66 Million - $2.65 Million	6,400 Added 8.82%	79,000 $27.4 Million
Q1 2021 May 13, 2021	BUY	$242.95 - $284.63 $3.38 Million - $3.96 Million	13,924 Added 23.73%	72,600 $20.3 Million
Q4 2020 Feb 12, 2021	BUY	$236.26 - $355.63 $10.1 Million - $15.2 Million	42,740 Added 268.2%	58,676 $14.4 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $1.06 Million - $1.4 Million	-4,100 Reduced 20.46%	15,936 $4.26 Million
Q1 2020 May 14, 2020	SELL	$268.85 - $341.04 $2.66 Million - $3.38 Million	-9,907 Reduced 33.09%	20,036 $6.34 Million
Q4 2019 Feb 13, 2020	SELL	$220.06 - $304.07 $2 Million - $2.76 Million	-9,067 Reduced 23.24%	29,943 $8.89 Million
Q3 2019 Nov 13, 2019	SELL	$217.44 - $243.88 $323,985 - $363,381	-1,490 Reduced 3.68%	39,010 $9.08 Million
Q2 2019 Aug 13, 2019	BUY	$219.29 - $241.72 $2.68 Million - $2.95 Million	12,200 Added 43.11%	40,500 $9.47 Million
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $4.88 Million - $7.63 Million	22,500 Added 387.93%	28,300 $6.69 Million
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $55,700 - $70,550	200 Added 3.57%	5,800 $1.75 Million
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $707,359 - $925,030	-2,410 Reduced 30.09%	5,600 $1.98 Million
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $5.71 Million - $6.81 Million	-22,190 Reduced 73.48%	8,010 $2.33 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $7.52 Million - $10.6 Million	28,900 Added 2223.08%	30,200 $8.27 Million
Q4 2017 Feb 14, 2018	SELL	$307.64 - $344.58 $55,375 - $62,024	-180 Reduced 12.16%	1,300 $414,000
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $6.47 Million - $7.58 Million	-23,004 Reduced 93.96%	1,480 $463,000
Q2 2017 Aug 14, 2017	BUY	N/A	24,484	24,484 $6.64 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

Vanguard Group Inc Valley Forge, PA

16.6M
Shares

$2.88 Billion
0.08% of portfolio
Primecap Management CO Pasadena, CA

16.3M
Shares

$2.84 Billion
2.78% of portfolio
Black Rock Inc. New York, NY

14.5M
Shares

$2.53 Billion
0.08% of portfolio
State Street Corp Boston, MA

7.1M
Shares

$1.23 Billion
0.07% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

5.68M
Shares

$987 Million
0.83% of portfolio

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track Jeremy Grantham's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.

Account